Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...

The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable ...

Two months after its treatment for Duchenne-related cardiomyopathy was rejected, the company aligned with the agency on a ...

Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in ...